NAD and Migraines

Intranasal Administration of Nicotinamide Adenine Dinucleotide Alleviates Headaches Associated with Migraine Pain: A Case Report

 Thompson, A., DiBlasio, P., Dyess, G.A., Broom, S.L., Mestayer, R.F, presented at Mississippi Academy of Sciences Conference, March 2022


An 87-year-old woman with a 50-year history of migraines received NAD/Lidocaine at 100 mg/mL, 0.5% per protocol of 0.5 mL, intranasally into each nostril via sphenocatheter. The patient also was prescribed Real NAD+ (150mg/day) sublinguql lozenges over a three-month period. 

Follow-up interviews were conducted at one week, six weeks, three months, and one year, with the following results:

The patient tolerated the treatment well, reported no adverse effects, and has not had a single recurring migraine.

MAS 2022 ATPDGDSB poster

Case report to be presented at the Society for Neuroscience, San Diego, CA, in November 2022.

Intranasal administration of nicotinamide adenine dinucleotide alleviates headaches associated with migraine headache pain and reduces adverse effects of anxiety disorders: A case report

*J. WHITE1, A. PODESTA2, G. A. DYESS1, S. L. BROOM1,3, R. F. MESTAYER1. Intranasal administration of nicotinamide adenine dinucleotide alleviates headaches associated with migraine headache pain and reduces adverse effects of anxiety disorders: A case report.

  1. NAD Research Inc., Springfield, Louisiana, 2. Podesta Wellness, Tulane Clinical Faculty, New Orleans, Louisiana 3. William Carey University, Hattiesburg, MS.

Introduction: Research suggests that Nicotinamide Adenine Dinucleotide (NAD+) is effective in treating clinical conditions associated with disease and aging due to its vital role in healthy cell functioning.  Clinicians around the U.S. developed intranasal (IN) NAD+ administration protocols directly on the sphenopalatine ganglion (SPG) for migraine/cluster headaches and symptoms associated with anxiety.  This case report describes a patient response to IN NAD+ experiencing symptoms associated with migraine headache, Agoraphobia, PTSD, and severe anxiety.

Methods: A 55-year-old male patient presented with disabling PTSD with paranoia, bipolar traits, and migraine/cluster headaches poorly controlled by traditional medications. Patient reported frequent panic attacks, debilitating headaches, anxiety with Agoraphobia, and history of attempted suicide. On 2/07/2020 the patient scored 27 on the Warwick-Edinburg Mental Well-being Scale (WEMWBS). Patient received NAD+ (0.375ml of 100mg/ml) and lidocaine (0.25ml of 20mg/1ml) into each nostril via sphenocatheter followed up by treatments at 1 and 4 weeks. Additional outcome measures were collected at 2m, 8m, and 1-year.

Findings: After the first session, patient reported needing less migraine medication and improved sleep.  After 3 days, patient reported less intense panic attacks during the day and cessation of nightly panic attacks. At 1 month, patient reported mild headaches and was able to taper off quetiapine and oxcarbazepine.  Between 1 and 4-weeks, he reported 2 cluster headaches while no longer taking sumatriptan or requiring oxygen. On 3/15/2020, the patient scored 45 on the WEMWBS, showing significant improvement despite being on less medication. At 1-year follow-up, patient reported reoccurrence of nightmares, but not needing rescue medications or oxygen.

Discussion: The mechanism of action for IN NAD+ application is unclear; however, data suggest that delivery directly on SPG facilitates the attenuation of migraine/cluster headaches and anxiety symptoms beyond medication therapy alone, with fewer side effects. NAD+ efficacy lessened over the extended break in treatment due to the COVID-19 pandemic, however significant dampening in symptoms was rapidly (< 4 days) observed, despite taking less medication.

Conclusion: Data show a rapid and sustained treatment effect of decreased severity and alleviation of migraine pain and anxiety symptoms resulted in enhanced quality of life measures and less need for medications to manage symptoms. Further studies are warranted to empirically validate NAD+ as an alternative or augmenting treatment approach in a subset of clinical populations.


Theme D: Sensory Systems

D.02.b. Headache, migraine. and trigeminal circuits

D.02.l. Non-opioid treatments


Theme G: Motivation and Emotion

G.06. Anxiety Disorders

G.06.a. Human studies and therapeutic approaches